PuSH - Publication Server of Helmholtz Zentrum München: SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Tzelepis, K.* ; De Braekeleer, E.* ; Aspris, D.* ; Barbieri, I.* ; Vijayabaskar, M.S.* ; Liu, W.-H. ; Gozdecka, M.* ; Metzakopian, E.* ; Toop, H.D.* ; Dudek, M.* ; Robson, S.C.* ; Hermida-Prado, F.* ; Yang, Y.H.* ; Babaei-Jadidi, R.* ; Garyfallos, D.A.* ; Ponstingl, H.* ; Dias, J.M.L.* ; Gallipoli, P.* ; Seiler, M.* ; Buonamici, S.* ; Vick, B. ; Bannister, A.J.* ; Rad, R.* ; Prinjha, R.K.* ; Marioni, J.C.* ; Huntly, B.* ; Batson, J.* ; Morris, J.C.* ; Pina, C.* ; Bradley, A.* ; Jeremias, I. ; Bates, D.O.* ; Yusa, K.* ; Kouzarides, T.* ; Vassiliou, G.S.*

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

Nat. Commun. 9:5378 (2018)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

We recently identified the splicing kinase gene SRPK1 as a genetic vulnerability of acute myeloid leukemia (AML). Here, we show that genetic or pharmacological inhibition of SRPK1 leads to cell cycle arrest, leukemic cell differentiation and prolonged survival of mice transplanted with MLL-rearranged AML. RNA-seq analysis demonstrates that SRPK1 inhibition leads to altered isoform levels of many genes including several with established roles in leukemogenesis such as MYB, BRD4 and MED24. We focus on BRD4 as its main isoforms have distinct molecular properties and find that SRPK1 inhibition produces a significant switch from the short to the long isoform at the mRNA and protein levels. This was associated with BRD4 eviction from genomic loci involved in leukemogenesis including BCL2 and MYC. We go on to show that this switch mediates at least part of the anti-leukemic effects of SRPK1 inhibition. Our findings reveal that SRPK1 represents a plausible new therapeutic target against AML.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

12.353

2.912